1
|
Wang QQ, Liu ZX, Wang P, Liu BY, Feng YP, Zhang Y, He HB, Yin T, Tang X, Wang YJ, Gou JX. Intratumoral injection of norcantharidin liposome emulsion hybrid delivery system amplifies the cancer-fighting effects of oral sorafenib against hepatocellular carcinoma. Colloids Surf B Biointerfaces 2023; 232:113599. [PMID: 37857183 DOI: 10.1016/j.colsurfb.2023.113599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Accepted: 10/14/2023] [Indexed: 10/21/2023]
Abstract
Interventional therapies are increasingly used in clinical trials for hepatocellular carcinoma (HCC). Sorafenib is the front-line remedy for HCC, however, chemoresistance occurs immutably and affects the effectiveness of treatment. In a previous study, a norcantharidin liposome emulsion hybrid (NLEH) delivery system for HCC was developed. This study aims to examine the therapeutic effects of the combination of intratumoral injection of NLEH and sorafenib in treating HCC. Sorafenib combined with NLEH activated the apoptosis pathway by synergistically upregulating caspase-9, promoting cytotoxicity, apoptosis (64.57%), and G2/M cell cycle arrest (48.96%). Norcantharidin could alleviate sorafenib resistance by counteracting sorafenib-induced phosphorylation of Akt. Additionally, intratumoral injection of NLEH exhibited a sustained accumulation in the tumor within 24 h and didn't distribute to other major organs. Intratumoral injection of NLEH in combination with oral sorafenib displayed the most potent tumor growth inhibitory effect (77.91%) in vivo. H&E staining results and the indicators of the renal and liver function tests demonstrated the safety of this combination therapy. Overall, these results showed that intratumoral injection of NLEH in combination with oral sorafenib treatment represented a rational potential therapeutic option for HCC.
Collapse
Affiliation(s)
- Qing-Qing Wang
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Zi-Xu Liu
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Ping Wang
- Department of Pharmaceutics, College of Pharmacy Sciences, Jilin University, Changchun, Jilin, China
| | - Bo-Yuan Liu
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Yu-Peng Feng
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Yu Zhang
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Hai-Bing He
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Tian Yin
- Department of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
| | - Xing Tang
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
| | - Yan-Jiao Wang
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
| | - Jing-Xin Gou
- School of Pharmaceutics Science, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
| |
Collapse
|
2
|
Miao RF, Tu J. LncRNA CDKN2B-AS1 interacts with LIN28B to exacerbate sepsis-induced acute lung injury by inducing HIF-1α/NLRP3-mediated pyroptosis. Kaohsiung J Med Sci 2023; 39:883-895. [PMID: 37265187 DOI: 10.1002/kjm2.12697] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 04/23/2023] [Accepted: 05/02/2023] [Indexed: 06/03/2023] Open
Abstract
Sepsis-associated acute lung injury (ALI) is a life-threatening condition in intensive care units with high mortality. LncRNAs have been confirmed to participate in the underlying pathogenesis of septic ALI. This study investigated the biological functions of lncRNA CDKN2B-AS1 in septic ALI and its potential mechanism.BEAS-2B cells were challenged with lipopolysaccharide (LPS) and mice were subjected to caecal ligation and puncture (CLP) to induce septic ALI in vitro and in vivo. The expression levels of CDKN2B-AS1, LIN28B, HIF-1α, and pyroptosis-related molecules were assessed by qRT-PCR or Western blotting. The production of IL-1β and IL-18 was detected by ELISA. BEAS-2B cell pyroptosis was examined by flow cytometry. The interaction between LIN28B and CDKN2B-AS1/HIF-1α was validated by RIP and RNA pull-down assays. Colocalization of CDKN2B-AS1 and LIN28B was observed by FISH. ALI was determined by HE staining, the lung wet-to-dry (W/D) weight ratio, inflammatory cell numbers, and total protein concentration in bronchoalveolar lavage fluid (BALF). Caspase-1 expression in the lung tissues was examined by immunohistochemical staining.CDKN2B-AS1 was upregulated in BEAS-2B cells after LPS stimulation. CDKN2B-AS1 knockdown inhibited pyroptosis in LPS-exposed BEAS-2B cells in vitro and the lung tissues of septic mice in vivo. Mechanistically, CDKN2B-AS1 interacted with LIN28B to enhance HIF-1α stability. Rescue experiments showed that HIF-1α overexpression counteracted the inhibitory effect of sh-CDKN2B-AS1 on LPS-induced pyroptosis. CDKN2B-AS1 bound to LIN28B to trigger NLRP3-mediated pyroptosis by stabilizing HIF-1α, which promoted sepsis-induced ALI. CDKN2B-AS1 might be a novel therapeutic target for this disease.
Collapse
Affiliation(s)
- Run-Feng Miao
- Department of Emergency, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu Province, People's Republic of China
| | - Jing Tu
- Department of Emergency, Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu Province, People's Republic of China
| |
Collapse
|
3
|
Chien HW, Chen YS, Wang K, Chiou HL, Yang SF, Hsieh YH. Norcantharidin attenuates epidermal growth factor-induced proliferation, EMT and motility in ARPE-19 cells by modulating the AKT/snail/E-cadherin axis. Life Sci 2022; 311:121157. [DOI: 10.1016/j.lfs.2022.121157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 10/27/2022] [Accepted: 11/04/2022] [Indexed: 11/09/2022]
|